CELL & GENE THERAPY INSIGHTS

Spotlight

Expert Insight

Considerations for the development of autologous CAR-T cell products

Alexander Davidson,
Gerardo Santiago Toledo,
Kostadinka Lilova,
Michael Merges,
Peter Jones
11 January 2022
Expert Insight

Innovator Insight

Enabling clinical grade manufacturing of gene-engineered NK cells

Nina Möker,
Rizwan Romee,
Evelyn Ullrich
5 January 2022
Innovator Insight

Improving allogeneic manufacturing workflows

Dr. Evan Zynda,
Dr. Aditi Singh
4 November 2021
Innovator Insight

Interview


Expert Roundtable

A ddPCR primer: advantages, challenges, and key considerations when adopting Droplet Digital PCR for viral vector manufacture

Lauren M Drouin,
Fabien Dorange,
Bryan Silvey,
Mark White,
Steven Pincus
13 December 2021
Expert Roundtable

FastFacts


Viewpoint

Driving CARs on the biomanufacturing road to clinical success

Chelsia Qiuxia Wang,
Andy Hee-Meng Tan
10 January 2022
Viewpoint

Translation and automation hurdles for cell therapies

Jenny A Prange,
Beatrix Rauch-Schmid
9 December 2021
Viewpoint

Vectors FOCUS

Enrichment of full rAAV capsids in a scalable, reproducible viral vector manufacturing platform

Adam Hejmowski,
Michelle Olson,
Anne MacIntyre,
Amanda Rose,
Kurt Boenning,
Julio Huato,
Mark Schofield,
Aydin Kavara,
Nick Marchand,
Mike Collins
13 December 2021
Innovator Insight

COVID-19 vaccine approvals: key lessons for mRNA therapeutics

Venkata Indurthi, PhD,
Joseph Barberio,
Scott Zobbi,
Dr. Christoph Kröner
6 December 2021
Poster

Report

Other articles

Webinars

Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

Kenneth Olsen, PhD
Kenneth Olsen, PhD, Senior R&D Scientist, Personalized Medicine Business Unit, Lonza
 Rachel Perret, PhD
Rachel Perret, PhD, Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research
23 November 2021
Webinar
Enabling clinical grade manufacturing of gene-engineered NK cells

Enabling clinical grade manufacturing of gene-engineered NK cells

Nina Möker
Nina Möker, R&D Reagents Manager, Allogeneic Cell Therapy, Miltenyi Biotec
Prof. Dr. Evelyn Ullrich
Prof. Dr. Evelyn Ullrich, Arbeitsgruppe Zelluläre Immunologie, Universitätsklinikum, Frankfurt am Main (kgu.de)
Rizwan Romee, MD
Rizwan Romee, MD, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
Volker Huppert
Volker Huppert, Chief Development Officer Glycostem Therapeutics
30 November 2021
Webinar
Developing stem cell therapies: expansion strategies and lessons learned

Developing stem cell therapies: expansion strategies and lessons learned

Shirley Mei, PhD, MSc
Shirley Mei, PhD, MSc, Investigator, OHRI
Lauralyn McIntyre, MD, MHSc, FRCPC
Lauralyn McIntyre, MD, MHSc, FRCPC, Senior Scientist, OHRI
Catherine Siler, PhD
Catherine Siler, PhD, Field Applications Scientist, Corning Life Sciences
8 December 2021
Webinar
Putting the patient first: New modalities of manufacturing for cell therapy through real-time process changes

Putting the patient first: New modalities of manufacturing for cell therapy through real-time process changes

Chelsea C. White III
Chelsea C. White III, Schneider National Chair of Transportation & Logistics, H. Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology
Professor Ben Wang
Professor Ben Wang, Gwaltney Chair in Manufacturing Systems, Executive Director, Georgia Institute of Technology
Dr. Kan Wang
Dr. Kan Wang, Senior Research Engineer, Georgia Tech Manufacturing Institute, Georgia Institute of Technology
9 December 2021
Webinar